Breast cancer subtype should also be considered: hormone receptor-negative and rapidly proliferating tumours may recur within 5 years after the first treatment, while the risk of relapse for hormone receptor-positive tumours remains constant for at least 10 years. This evidence concerns the gene NR4A1 and breast carcinoma.